Thalidomide For Brain Tumors

29 May 1997

- EntreMed has reported data from a Phase II trial of thalidomidewhich demonstrated a 50% biological response in patients with glioblastoma multiforme. 12 patients saw disease stabilize, two experienced a reduction in tumor size of 50% and two saw tumor size reduction of less than 50%. The treatment was also well-tolerated, even at high doses. These data support further trials in glioblastoma. In a separate Phase II trial, 60% of patients (three of five) with Kaposi's sarcoma achieved a response to the treatment, defined as a greater than 50% reduction in lesions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight